Redhill Biopharma Ltd
NASDAQ:RDHL
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.4521
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.4657/ 1
  • Ask / Lots
    0.4700/ 2
  • Open / Previous Close
    0.0000 / 0.4521
  • Day Range
    ---
  • 52 Week Range
    0.2570
    3.2800
  • Volume
    1,080

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 7:43AM ET on Monday May 06, 2024 by MT Newswires
      Companies Mentioned: RDHL
      07:43 AM EDT, 05/06/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Monday it was awarded a new patent in China for investigational drug opaganib as a therapy to inhibit single-stranded RNA virus replication, notably Ebola virus disease. The pa...

    • 7:00AM ET on Monday May 06, 2024 by Dow Jones
      Companies Mentioned: RDHL

      This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will, " "plans," "expects," "anticipates," "projects," "predicts," "estimates, " "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107, the risk that HB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required, as well as risks and uncertainties associated with the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia(R); (v) the Company's ability to successfully commercialize and promote Talicia(R) and Aemcolo(R); (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

  • Apr 24, 2024

  • Apr 8, 2024

      Show headlines and story abstract

    • 9:23AM ET on Monday Apr 08, 2024 by PR Newswire
      Companies Mentioned: RDHL

      RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base

      Focused externally funded R&D:

    • 9:23AM ET on Monday Apr 08, 2024 by Dow Jones
      Companies Mentioned: RDHL
      Depreciation 1,445 2,136 1,914 Amortization of intangible assets 545 6,018 16,235 Gains from the transfer of rights in Movantik(R) and extinguishment of debt obligations, (see below) (56,082) -- -- Gains from early termination of leases and impairment of fixed assets, net (543) -- -- Non-cash expenses related to borrowing and payable in respect of intangible assets purchase -- 33,151 5,366 Fair value (gains) losses on derivative financial instruments and changes in royalty obligation 5,359 (13,422) 5 Loss from modification of warrants terms as part of a new issuance 1,459 -- -- Issuance costs in respect of warrants 2,034 958 -- Exchange differences and revaluation of bank deposits 19 (40) 118 --------- -------- -------- (44,117) 34,476 33,850 --------- -------- -------- Changes in assets and liability items: Decrease (increase) in trade receivables 31,930 (2,845) (3,021) Decrease in prepaid expenses and other receivables 1,586 274 860 Decrease (increase) in inventories 2,387 3,801 (8,285) Increase (decrease) in accounts payable (952) (7,434) 111 (Decrease) in accrued expenses and other liabilities (13,354) (2,947) (3,186) Increase (decrease) in allowance for deductions from revenue (37,216) 17,159 12,368 --------- -------- -------- (15,619) 8,008 (1,153) --------- -------- -------- Net cash used in operating activities (35,820) (29,185) (65,047) --------- -------- -------- INVESTING ACTIVITIES: Purchase of fixed assets (11) (198) (115) Change in investment in current bank deposits 15 8,500 (8,500) Proceeds from sale of financial assets at fair value through profit or loss -- -- 475 --------- -------- -------- Net cash provided by (used in) investing activities 4 8,302 (8,140) --------- -------- -------- FINANCING ACTIVITIES: Proceeds from issuance of ordinary shares and warrants, net of issuance costs 13,959 23,806 78,536 Exercise of options into ordinary shares -- -- 4,006 Repayment of payable in respect of intangible asset purchase (6,555) (10,878) (7,397) Decrease in restricted cash 15,210 -- -- Payment of principal with respect to lease liabilities (1,175) (1,475) (1,683) --------- -------- -------- Net cash provided by financing activities 21,439 11,453 73,462 --------- -------- -------- INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (14,377) (9,430) 275 EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS (22) (76) (96) BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 19,968 29,474 29,295 --------- -------- -------- BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD 5,569 19,968 29,474 ========= ======== ======== SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH 138 84 47 --------- -------- -------- SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH 367 8,182 11,280 --------- -------- -------- SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES: Acquisition of right-of-use assets by means of lease liabilities 270 5,590 303 --------- -------- -------- Decrease in lease liability (with corresponding decrease in right of use asset in amount of $4,697 in 2023 and $534 in 2022) resulting from early termination of lease. 5,413 587 -- --------- -------- -------- Transfer of rights in Movantik(R) and extinguishment of debt obligations: Decrease in Intangible asset (59,503) Decrease in Inventories (4,233) Decrease in Payable in respect of Intangible asset 4,602 Decrease in Borrowing 115,216 --------- Gains from the transfer of the rights in Movantik(R) and extinguishment of debt obligations 56,082 =========

Peers Headlines